PMID- 24672110
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140327
LR  - 20211021
IS  - 0011-393X (Print)
IS  - 0011-393X (Linking)
VI  - 66
IP  - 1
DP  - 2005 Jan
TI  - Effects of a single, 24-hour, low-dose intravenous dobutamine infusion on left 
      ventricular myocardial performance index in congestive heart failure: A 
      prospective, nonrandomized study.
PG  - 35-44
LID - 10.1016/j.curtheres.2005.03.002 [doi]
AB  - BACKGROUND: Dobutamine, a predominantly beta-adrenergic sympathomimeticagent, is 
      used for improving left ventricular (LV) systolic performance with different 
      dosing regimens in patients with congestive heart failure (CHF). Myocardial 
      performance index (MPI) is an indicator of LV global function that is correlated 
      with LV end-diastolic pressure, and it is increased in CHF. OBJECTIVE: The 
      purpose of this study was to examine the effects of a single, 24-hour, low-dose, 
      IV dobutamine infusion on LV systolic and diastolic function and on MPI in CHF as 
      an indicator of LV global function, as well as the adverse effects (AEs) of the 
      infusion. METHODS: This prospective, nonrandomized study was conducted at 
      theDepartment of Cardiology, Baskent University Hospital, Ankara, Turkey. Adult 
      patients with LV ejection fraction (EF) <35%, sinus rhythm, and symptomatic CHF 
      were treated using a standard protocol for at least 4 weeks. At the end of this 
      period, patients with symptomatic CHF and EF <35% underwent echocardiography that 
      included measuring isovolumic relaxation and contraction times (IRT and ICT, 
      respectively) and LV ejection time (ET), and calculating LV MPI using the formula 
      MPI = (IRT + ICT)/ET Dobutamine 2.5 mug/kg . min was then infused intravenously 
      for 24 hours. Echocardiography was repeated 24 hours later and values were 
      compared with preinfusion data. Patients were observed and monitored for CHF 
      symptoms and AEs for 24 hours. RESULTS: Forty-three patients were enrolled in the 
      study, and 31 (22 men,9 women; mean [SD] age, 67.55 [11.78] years) continued 
      after the 4-week standard-treatment period. Mean (SD) heart rate (74.93 [20.15] 
      vs 80.23 [13.74] bpm, respectively), systolic blood pressure (129.00 [19.23] vs 
      126.67 [23.79] mm Hg), and diastolic blood pressure (75.80 [11.26] vs 74.96 
      [8.30] mm Hg) were statistically similar before and after the infusion. The mean 
      (SD) end-diastolic volume was statistically similar to the preinfusion value 
      (215.87 [76.74] vs 211.08 [65.51] mL); however, the mean (SD) end-systolic volume 
      was significantly reduced (163.80 [63.86] vs 146.74 [53.12] mL; P = 0.01). Mean 
      (SD) EF (25.33% [7.77%] vs 30.45% [7.63%]; P = 0.001) and stroke volume (SV) 
      (54.92 [22.30] vs 63.59 [23.91] mL; P = 0.04) increased significantly. The mean 
      (SD) early:late diastolic flow velocity (E/A ratio) (1.58 [1.36] vs 1.65 [1.27]), 
      IRT (107.03 [35.37] vs 100.42 [34.32] ms), ICT (96.61 [34.27] vs 86.35 [44.80] 
      ms), ET (240.65 [33.28] vs 243.48 [33.54] ms), and MPI (0.81% [0.28%] vs 0.78% 
      [0.31%]) did not change significantly after dobutamine infusion. No AEs were 
      observed. CONCLUSIONS: In this study of adult patients with symptomatic CHF, a 
      single, 24-hour, low-dose, IV dobutamine infusion (2.5 mug/kg . min) was 
      associated with decreased LV end-systolic volume and increased SV and EF However, 
      LV diastolic function parameters, isovolumic time intervals, ET, and MPI were 
      statistically similar to preinfusion values. The infusion was well tolerated.
FAU - Ulucam, Melek
AU  - Ulucam M
AD  - Department of Cardiology, Baskent University Hospital, Ankara, Turkey.
FAU - Korkmaz, Mehmet Emin
AU  - Korkmaz ME
AD  - Department of Cardiology, Guven Hospital, Ankara, Turkey.
FAU - Muderrisoglu, Haldun
AU  - Muderrisoglu H
AD  - Department of Cardiology, Baskent University Hospital, Ankara, Turkey.
FAU - Ozin, Bulent
AU  - Ozin B
AD  - Department of Cardiology, Baskent University Hospital, Ankara, Turkey.
FAU - Yildirir, Aylin
AU  - Yildirir A
AD  - Department of Cardiology, Baskent University Hospital, Ankara, Turkey.
FAU - Tayfun, Egemen
AU  - Tayfun E
AD  - Department of Cardiology, Baskent University Hospital, Ankara, Turkey.
FAU - Aydinalp, Alp
AU  - Aydinalp A
AD  - Department of Cardiology, Baskent University Hospital, Ankara, Turkey.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Ther Res Clin Exp
JT  - Current therapeutic research, clinical and experimental
JID - 0372621
PMC - PMC3964544
OTO - NOTNLM
OT  - dobutamine
OT  - heart failure
OT  - myocardial performance index
EDAT- 2005/01/01 00:00
MHDA- 2005/01/01 00:01
PMCR- 2005/01/01
CRDT- 2014/03/28 06:00
PHST- 2004/12/23 00:00 [accepted]
PHST- 2014/03/28 06:00 [entrez]
PHST- 2005/01/01 00:00 [pubmed]
PHST- 2005/01/01 00:01 [medline]
PHST- 2005/01/01 00:00 [pmc-release]
AID - S0011-393X(05)00018-4 [pii]
AID - 10.1016/j.curtheres.2005.03.002 [doi]
PST - ppublish
SO  - Curr Ther Res Clin Exp. 2005 Jan;66(1):35-44. doi: 
      10.1016/j.curtheres.2005.03.002.